Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment

Naoki Nishio; Stan van Keulen; Nynke S. van den Berg; Guolan Lu; Ethan P. LaRochelle; Scott C. Davis; Brock A. Martin; Shayan Fakurnejad; Quan Zhou; Andrew C. Birkeland; Michael J. Kaplan; Vasu Divi; A. Dimitrios Colevas; Brian W. Pogue; Eben L. Rosenthal

doi:10.1002/hed.25964

Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment

Naoki Nishio, Stan van Keulen, Nynke S. van den Berg, Guolan Lu, Ethan P. LaRochelle, Scott C. Davis, Brock A. Martin, Shayan Fakurnejad, Quan Zhou, Andrew C. Birkeland, Michael J. Kaplan, Vasu Divi, A. Dimitrios Colevas, Brian W. Pogue, Eben L. Rosenthal^*

^*Corresponding author for this work

Maxillofacial Surgery (VUmc)

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.

Original language	English
Pages (from-to)	59-66
Number of pages	8
Journal	Head and Neck
Volume	42
Issue number	1
Early online date	1 Oct 2019
DOIs	https://doi.org/10.1002/hed.25964
Publication status	Published - Jan 2020

Bibliographical note

Funding Information:
This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681).

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Funding

This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681).

Funders	Funder number
Netherlands Organization for Scientific Research	019.171LW.022
Stanford Comprehensive Cancer Center
Stanford Molecular Imaging Scholars	T32 CA118681
Stanford University School of Medicine Medical Scholars Program
National Institutes of Health
National Cancer Institute	R01CA190306, T32CA118681
National Cancer Institute

Keywords

EGFR
fluorescence dosimetry
fluorescence-guided tissue preselection
head and neck cancer
panitumumab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.25964

Persistent URL (handle)

Persistent link

Cite this

Nishio, N., van Keulen, S., van den Berg, N. S., Lu, G., LaRochelle, E. P., Davis, S. C., Martin, B. A., Fakurnejad, S., Zhou, Q., Birkeland, A. C., Kaplan, M. J., Divi, V., Colevas, A. D., Pogue, B. W., & Rosenthal, E. L. (2020). Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment. Head and Neck, 42(1), 59-66. https://doi.org/10.1002/hed.25964

@article{bddfe16270574a08bd7d4174dbb9311b,

title = "Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment",

abstract = "Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.",

keywords = "EGFR, fluorescence dosimetry, fluorescence-guided tissue preselection, head and neck cancer, panitumumab",

author = "Naoki Nishio and {van Keulen}, Stan and {van den Berg}, {Nynke S.} and Guolan Lu and LaRochelle, {Ethan P.} and Davis, {Scott C.} and Martin, {Brock A.} and Shayan Fakurnejad and Quan Zhou and Birkeland, {Andrew C.} and Kaplan, {Michael J.} and Vasu Divi and Colevas, {A. Dimitrios} and Pogue, {Brian W.} and Rosenthal, {Eben L.}",

note = "Funding Information: This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681). Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2020",

month = jan,

doi = "10.1002/hed.25964",

language = "English",

volume = "42",

pages = "59--66",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

Nishio, N, van Keulen, S, van den Berg, NS, Lu, G, LaRochelle, EP, Davis, SC, Martin, BA, Fakurnejad, S, Zhou, Q, Birkeland, AC, Kaplan, MJ, Divi, V, Colevas, AD, Pogue, BW & Rosenthal, EL 2020, 'Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment', Head and Neck, vol. 42, no. 1, pp. 59-66. https://doi.org/10.1002/hed.25964

Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment. / Nishio, Naoki; van Keulen, Stan; van den Berg, Nynke S. et al.
In: Head and Neck, Vol. 42, No. 1, 01.2020, p. 59-66.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment

AU - Nishio, Naoki

AU - van Keulen, Stan

AU - van den Berg, Nynke S.

AU - Lu, Guolan

AU - LaRochelle, Ethan P.

AU - Davis, Scott C.

AU - Martin, Brock A.

AU - Fakurnejad, Shayan

AU - Zhou, Quan

AU - Birkeland, Andrew C.

AU - Kaplan, Michael J.

AU - Divi, Vasu

AU - Colevas, A. Dimitrios

AU - Pogue, Brian W.

AU - Rosenthal, Eben L.

N1 - Funding Information: This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681). Publisher Copyright: © 2019 Wiley Periodicals, Inc.

PY - 2020/1

Y1 - 2020/1

N2 - Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.

AB - Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.

KW - EGFR

KW - fluorescence dosimetry

KW - fluorescence-guided tissue preselection

KW - head and neck cancer

KW - panitumumab

UR - http://www.scopus.com/inward/record.url?scp=85073973363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073973363&partnerID=8YFLogxK

U2 - 10.1002/hed.25964

DO - 10.1002/hed.25964

M3 - Article

C2 - 31571335

AN - SCOPUS:85073973363

SN - 1043-3074

VL - 42

SP - 59

EP - 66

JO - Head and Neck

JF - Head and Neck

IS - 1

ER -

Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessment

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this